Published in J Virol on July 18, 2007
Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature (2013) 4.45
Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed. J Clin Invest (2008) 2.21
Attenuation of V- or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys. J Virol (2008) 1.36
Measles virus selectively blind to signaling lymphocytic activation molecule (SLAM; CD150) is attenuated and induces strong adaptive immune responses in rhesus monkeys. J Virol (2010) 1.25
Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein. Vaccine (2010) 1.00
ATP hydrolysis by the viral RNA sensor RIG-I prevents unintentional recognition of self-RNA. Elife (2015) 0.98
In vivo ligands of MDA5 and RIG-I in measles virus-infected cells. PLoS Pathog (2014) 0.97
Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis. Mol Ther (2011) 0.96
A recombinant measles virus unable to antagonize STAT1 function cannot control inflammation and is attenuated in rhesus monkeys. J Virol (2010) 0.94
Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster. J Virol (2012) 0.92
Protective anti-hepatitis B virus responses in rhesus monkeys primed with a vectored measles virus and boosted with a single dose of hepatitis B surface antigen. J Virol (2009) 0.91
Measles virus C protein impairs production of defective copyback double-stranded viral RNA and activation of protein kinase R. J Virol (2013) 0.89
Cell tropism and pathogenesis of measles virus in monkeys. Front Microbiol (2012) 0.86
Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector. Hum Vaccin Immunother (2013) 0.83
Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics. Virology (2015) 0.83
Measles virus entry through the signaling lymphocyte activation molecule governs efficacy of mantle cell lymphoma radiovirotherapy. Mol Ther (2013) 0.82
Vaccine platform recombinant measles virus. Virus Genes (2017) 0.81
Live-attenuated measles virus vaccine targets dendritic cells and macrophages in muscle of nonhuman primates. J Virol (2014) 0.81
A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform. J Virol (2015) 0.81
Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector. Hum Vaccin Immunother (2013) 0.80
New vaccine design based on defective genomes that combines features of attenuated and inactivated vaccines. PLoS One (2010) 0.79
Development of measles virus-based shielded oncolytic vectors: suitability of other paramyxovirus glycoproteins. Cancer Gene Ther (2013) 0.79
Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350. Open Virol J (2012) 0.78
Immunogenic Subviral Particles Displaying Domain III of Dengue 2 Envelope Protein Vectored by Measles Virus. Vaccines (Basel) (2015) 0.77
The successful induction of T-cell and antibody responses by a recombinant measles virus-vectored tetravalent dengue vaccine provides partial protection against dengue-2 infection. Hum Vaccin Immunother (2016) 0.77
Measles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogens. Vaccine (2013) 0.77
An immune competent mouse model for the characterization of recombinant measles vaccines. Hum Vaccin Immunother (2014) 0.77
Nuclear reprogramming with a non-integrating human RNA virus. Stem Cell Res Ther (2015) 0.76
Generation of a More Immunogenic Measles Vaccine by Increasing Its Hemagglutinin Expression. J Virol (2016) 0.75
Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination. Hum Vaccin Immunother (2015) 0.75
Replicon RNA Viral Vectors as Vaccines. Vaccines (Basel) (2016) 0.75
Multicenter Safety and Immunogenicity Trial of an Attenuated Measles Vaccine for NHP. Comp Med (2015) 0.75
Rescue of measles viruses from cloned DNA. EMBO J (1995) 7.87
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription. Cell (1981) 5.38
Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature (1983) 5.25
Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited. J Virol (1998) 3.60
Specific inhibition of paramyxovirus and myxovirus replication by oligopeptides with amino acid sequences similar to those at the N-termini of the F1 or HA2 viral polypeptides. Virology (1980) 3.53
Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence. J Virol (1998) 3.27
Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J Virol (2001) 3.27
Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature (1984) 3.03
Measles virus spread and pathogenesis in genetically modified mice. J Virol (1998) 2.84
Development of a new vaccine for the prevention of Lassa fever. PLoS Med (2005) 2.71
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood (2003) 2.67
Altered transcription of a defective measles virus genome derived from a diseased human brain. EMBO J (1987) 2.67
A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory. Pediatrics (2001) 2.55
Biophysical properties of Australia antigen. J Virol (1969) 2.45
Cell fusion by the envelope glycoproteins of persistent measles viruses which caused lethal human brain disease. J Virol (1993) 2.38
Successes and failures in measles control. J Infect Dis (1994) 1.84
Tropism illuminated: lymphocyte-based pathways blazed by lethal morbillivirus through the host immune system. Proc Natl Acad Sci U S A (2004) 1.84
Experimental measles. I. Pathogenesis in the normal and the immunized host. Virology (1997) 1.83
Tyrosine 110 in the measles virus phosphoprotein is required to block STAT1 phosphorylation. Virology (2006) 1.80
Viral replication and development of specific immunity in macaques after infection with different measles virus strains. J Infect Dis (1994) 1.65
Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs (2003) 1.63
Dissection of measles virus V protein in relation to its ability to block alpha/beta interferon signal transduction. J Gen Virol (2004) 1.59
A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol (2006) 1.58
Polyploid measles virus with hexameric genome length. EMBO J (2002) 1.55
Nonsegmented negative-strand viruses as vaccine vectors. J Virol (2006) 1.53
Comparison of predicted amino acid sequences of measles virus strains in the Edmonston vaccine lineage. J Virol (2001) 1.47
Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis (2004) 1.46
Dynamics of viral RNA synthesis during measles virus infection. J Virol (2005) 1.44
Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. Vaccine (2001) 1.39
A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J Virol (1999) 1.33
Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. J Infect Dis (1997) 1.29
A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol (2003) 1.28
Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc Natl Acad Sci U S A (1989) 1.27
Experimental measles. II. Infection and immunity in the rhesus macaque. Virology (1997) 1.25
Attenuated measles virus as a vaccine vector. Vaccine (2007) 1.13
Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses. Vaccine (2001) 1.10
Analysis of the noncoding regions of measles virus strains in the Edmonston vaccine lineage. J Virol (2001) 1.08
Development of immunogenic recombinant Oka varicella vaccine expressing hepatitis B virus surface antigen. J Gen Virol (1991) 1.06
Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine (2004) 1.01
Eradication of vaccine-preventable diseases. Annu Rev Public Health (1999) 1.00
Protection against challenge with measles virus (MV) in infant macaques by an MV DNA vaccine administered in the presence of neutralizing antibody. J Infect Dis (2004) 0.98
Toward novel vaccines and therapies based on negative-strand RNA viruses. Curr Top Microbiol Immunol (2004) 0.94
Monitoring vaccine safety during measles mass immunization campaigns: clinical and programmatic issues. J Infect Dis (2003) 0.90
Novel immunogenicity of Oka varicella vaccine vector expressing hepatitis B surface antigen. J Infect Dis (2000) 0.83
Measles campaign's "historic victory" for global public health. BMJ (2007) 0.78
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum (2002) 3.96
Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature (2011) 2.94
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood (2003) 2.67
Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model. J Virol (2004) 2.42
Targeted cell entry of lentiviral vectors. Mol Ther (2008) 2.34
Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed. J Clin Invest (2008) 2.21
Strength of envelope protein interaction modulates cytopathicity of measles virus. J Virol (2002) 1.97
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum (2004) 1.89
CD46 in meningococcal disease. Science (2003) 1.84
Tropism illuminated: lymphocyte-based pathways blazed by lethal morbillivirus through the host immune system. Proc Natl Acad Sci U S A (2004) 1.84
Tyrosine 110 in the measles virus phosphoprotein is required to block STAT1 phosphorylation. Virology (2006) 1.80
The heads of the measles virus attachment protein move to transmit the fusion-triggering signal. Nat Struct Mol Biol (2011) 1.61
Polyploid measles virus with hexameric genome length. EMBO J (2002) 1.55
A ferret model of canine distemper virus virulence and immunosuppression. J Virol (2003) 1.55
Receptor (SLAM [CD150]) recognition and the V protein sustain swift lymphocyte-based invasion of mucosal tissue and lymphatic organs by a morbillivirus. J Virol (2006) 1.54
RNA-specific adenosine deaminase ADAR1 suppresses measles virus-induced apoptosis and activation of protein kinase PKR. J Biol Chem (2009) 1.53
Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J Virol (2003) 1.53
Detection of antigen-specific T cell interferon gamma expression by ELISPOT and cytokine flow cytometry assays in rhesus macaques. J Immunol Methods (2003) 1.47
Efficacy of influenza vaccination of elderly rhesus macaques is dramatically improved by addition of a cationic lipid/DNA adjuvant. J Infect Dis (2013) 1.47
Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res (2007) 1.41
Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res (2006) 1.40
Antibody-targeted cell fusion. Nat Biotechnol (2004) 1.39
Attenuation of V- or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys. J Virol (2008) 1.36
Dynamic interaction of the measles virus hemagglutinin with its receptor signaling lymphocytic activation molecule (SLAM, CD150). J Biol Chem (2008) 1.29
Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood (2002) 1.27
Detection of measles virus RNA in whole blood stored on filter paper. J Med Virol (2002) 1.25
Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate (2009) 1.25
Measles virus selectively blind to signaling lymphocytic activation molecule (SLAM; CD150) is attenuated and induces strong adaptive immune responses in rhesus monkeys. J Virol (2010) 1.25
Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res (2003) 1.23
Personality and serotonin transporter genotype interact with social context to affect immunity and viral set-point in simian immunodeficiency virus disease. Brain Behav Immun (2007) 1.23
Efficiency of measles virus entry and dissemination through different receptors. J Virol (2002) 1.22
An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther (2007) 1.21
Measles virus phosphoprotein gene products: conformational flexibility of the P/V protein amino-terminal domain and C protein infectivity factor function. J Virol (2004) 1.21
Canine distemper virus uses both the anterograde and the hematogenous pathway for neuroinvasion. J Virol (2006) 1.20
Measles virus preferentially transduces the basolateral surface of well-differentiated human airway epithelia. J Virol (2002) 1.18
Protein kinase PKR mediates the apoptosis induction and growth restriction phenotypes of C protein-deficient measles virus. J Virol (2008) 1.18
Base of the measles virus fusion trimer head receives the signal that triggers membrane fusion. J Biol Chem (2012) 1.18
Mechanisms of protein kinase PKR-mediated amplification of beta interferon induction by C protein-deficient measles virus. J Virol (2010) 1.18
Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clin Rheumatol (2004) 1.18
Nearby clusters of hemagglutinin residues sustain SLAM-dependent canine distemper virus entry in peripheral blood mononuclear cells. J Virol (2005) 1.17
Species B adenovirus serotypes 3, 7, 11 and 35 share similar binding sites on the membrane cofactor protein CD46 receptor. J Gen Virol (2007) 1.15
Measles virus vaccine attenuation: suboptimal infection of lymphatic tissue and tropism alteration. J Infect Dis (2007) 1.15
MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism. Mol Ther (2011) 1.15
Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res (2006) 1.12
Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of depo-provera before intravaginal challenge with simian immunodeficiency virus mac239. J Infect Dis (2004) 1.11
Membrane fusion triggering: three modules with different structure and function in the upper half of the measles virus attachment protein stalk. J Biol Chem (2012) 1.07
N-linked glycans with similar location in the fusion protein head modulate paramyxovirus fusion. J Virol (2003) 1.07
Measles virus V protein inhibits p53 family member p73. J Virol (2006) 1.06
In vitro canine distemper virus infection of canine lymphoid cells: a prelude to oncolytic therapy for lymphoma. Clin Cancer Res (2005) 1.05
Measles virus replication in lymphatic cells and organs of CD150 (SLAM) transgenic mice. Proc Natl Acad Sci U S A (2005) 1.05
Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice. Hum Gene Ther (2003) 1.03
Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. J Rheumatol (2010) 1.02
Limited dissemination of pathogenic SIV after vaginal challenge of rhesus monkeys immunized with a live, attenuated lentivirus. Virology (2009) 1.01
Interferon-induced expression of MxA in the respiratory tract of rhesus macaques is suppressed by influenza virus replication. J Immunol (2008) 1.01
Canine distemper virus epithelial cell infection is required for clinical disease but not for immunosuppression. J Virol (2012) 0.99
Depo-Provera abrogates attenuated lentivirus-induced protection in male rhesus macaques challenged intravenously with pathogenic SIVmac239. J Med Primatol (2007) 0.98
Protection against challenge with measles virus (MV) in infant macaques by an MV DNA vaccine administered in the presence of neutralizing antibody. J Infect Dis (2004) 0.98
Amino-terminal precursor sequence modulates canine distemper virus fusion protein function. J Virol (2002) 0.97
DNA vaccination of infants in the presence of maternal antibody: a measles model in the primate. Virology (2003) 0.96
Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis. Mol Ther (2011) 0.96
Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone ® in rhesus macaques. Vaccine (2010) 0.95
A recombinant measles virus unable to antagonize STAT1 function cannot control inflammation and is attenuated in rhesus monkeys. J Virol (2010) 0.94
Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster. J Virol (2012) 0.92
Interaction of measles virus vectors with Auger electron emitting radioisotopes. Biochem Biophys Res Commun (2005) 0.92
Nectin-4-dependent measles virus spread to the cynomolgus monkey tracheal epithelium: role of infected immune cells infiltrating the lamina propria. J Virol (2012) 0.91
Protective anti-hepatitis B virus responses in rhesus monkeys primed with a vectored measles virus and boosted with a single dose of hepatitis B surface antigen. J Virol (2009) 0.91
Targeted entry of enveloped viruses: measles and herpes simplex virus I. Curr Opin Virol (2011) 0.90
Measles virus C protein impairs production of defective copyback double-stranded viral RNA and activation of protein kinase R. J Virol (2013) 0.89
Canine distemper virus and measles virus fusion glycoprotein trimers: partial membrane-proximal ectodomain cleavage enhances function. J Virol (2004) 0.89
Genetic changes that affect the virulence of measles virus in a rhesus macaque model. Virology (2007) 0.88
DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety. Mol Ther (2013) 0.88
Hydrophobic and charged residues in the central segment of the measles virus hemagglutinin stalk mediate transmission of the fusion-triggering signal. J Virol (2013) 0.88
Connections matter--how viruses use cell–cell adhesion components. J Cell Sci (2015) 0.87